Dynocardia

Company overview

Dynocardia is a Cambridge, Massachusetts medical technology company founded in 2018 with support from Tufts University and MIT. It is developing ViTrack, a proprietary wrist-worn platform for continuous, non-invasive blood-pressure monitoring.

ViTrack combines an optomechanical sensor with computer vision to measure movement over the radial artery and derive blood-pressure waveforms. Its initial development focus is hospital monitoring, particularly operating rooms and intensive care.

Founder and CEO Mohan Thanikachalam is a cardiovascular surgeon. The company also describes research and potential applications in remote monitoring, hypertension management and maternal health. ViTrack remains in development and clinical validation while the company works toward FDA submission.

^{[1][3][4][6][7][8]}

Products & regulatory status How does MedTechIndex get this information?

Summary

Dynocardia’s June 2026 update describes verification and validation of a production-grade ViTrack hospital device to enable FDA 510(k) submission. The company’s grant announcements identify the device as not yet available for U.S. use pending submission and clearance. ^[5][8]

ViTrack is being evaluated against invasive arterial-line measurements. Company-reported clinical testing includes continuous waveforms and blood-pressure readings every 20 seconds; these research results are distinct from a marketing authorization. ^[5][8]

Regulatory snapshot How to read this snapshot

U.S. FDA

—

510(k) clearances

—

De Novo grants

—

PMA approvals

—

Recall events

Latest recorded source review: 2026-11-01.

Scope: selected product families.

Commercial portfolio snapshot

No commercially marketed product portfolio has been established in the reviewed material.

Commercial development

Wearable cardiovascular monitoring

ViTrack continuous blood-pressure monitoring platform ↗

Wrist-worn device and connected platform under development for continuous systolic and diastolic blood-pressure monitoring without an inflatable arm cuff. An optomechanical sensor and computer vision analyze tissue displacement over the radial artery, with motion-correction technology intended to support monitoring during patient movement. Initial development targets hospital care; additional vital-sign and out-of-hospital applications remain research and development objectives. ^{[1][2][5][3][8]}

Development and clinical validation · working toward FDA submission